Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
| Buy | Overweight | Hold | Underweight | Sell |
|---|---|---|---|---|
| 3 | 0 | 0 | 0 | 0 |
Analyst Firms Making Recommendations1
- Needham
- Evercore ISI Group
- SVB Leerink
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Heron Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 11/15/2023 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 198.53% | Needham | Serge Belanger | $5 → $4 | Maintains | Buy | Get Alert |
| 08/15/2023 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 273.16% | Needham | Serge Belanger | → $5 | Reiterates | Buy → Buy | Get Alert |
| 07/25/2023 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 273.16% | Needham | Serge Belanger | $6 → $5 | Maintains | Buy | Get Alert |
| 05/12/2023 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 347.79% | Needham | Serge Belanger | $7 → $6 | Maintains | Buy | Get Alert |
| 04/21/2023 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 422.43% | Needham | Serge Belanger | → $7 | Reiterates | → Buy | Get Alert |
| 03/24/2023 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 646.32% | Evercore ISI Group | Shweta Khajuria | $15 → $10 | Maintains | Outperform | Get Alert |
| 03/24/2023 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 422.43% | Needham | Serge Belanger | $8 → $7 | Maintains | Buy | Get Alert |
| 11/09/2022 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 497.06% | Needham | Serge Belanger | $10 → $8 | Maintains | Buy | Get Alert |
| 06/30/2022 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 646.32% | Needham | Serge Belanger | $14 → $10 | Maintains | Buy | Get Alert |
| 05/10/2022 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 944.85% | Needham | Serge Belanger | $16 → $14 | Maintains | Buy | Get Alert |
| 12/02/2020 | HRTX | Buy Now | Heron Therapeutics | $1.34 | 1691.18% | SVB Leerink | — | — | Maintains | Outperform | Get Alert |
What is the target price for Heron Therapeutics (HRTX)?
The latest price target for Heron Therapeutics (NASDAQ: HRTX) was reported by Needham on November 15, 2023. The analyst firm set a price target for $4.00 expecting HRTX to rise to within 12 months (a possible 198.53% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Heron Therapeutics (HRTX)?
The latest analyst rating for Heron Therapeutics (NASDAQ: HRTX) was provided by Needham, and Heron Therapeutics maintained their buy rating.
When is the next analyst rating going to be posted or updated for Heron Therapeutics (HRTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Heron Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Heron Therapeutics was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
Is the Analyst Rating Heron Therapeutics (HRTX) correct?
While ratings are subjective and will change, the latest Heron Therapeutics (HRTX) rating was a maintained with a price target of $5.00 to $4.00. The current price Heron Therapeutics (HRTX) is trading at is $1.34, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.